Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
US-9359336-B2 · Jun 7, 2016 · US
Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
US10011593B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10011593-B2 |
| Application number | US-201715490533-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 18, 2017 |
| Priority date | Oct 9, 2014 |
| Publication date | Jul 3, 2018 |
| Grant date | Jul 3, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein: R is selected from the group consisting of: 2. The compound of claim 1 , wherein the compound is 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-{2-[5-(2H-tetrazol-5-yl)pyridin-3-yl]-1-benzothien-5-yl}urea, or a pharmaceutically acceptable salt thereof. 3. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable adjuvant, diluent or carrier. 4. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to claim 2 and a pharmaceutically acceptable adjuvant, diluent or carrier. 5. The compound of claim 1 , wherein the compound is 1-(2-{2-amino-5-[1-(3-hydroxypropyl)-1H-tetrazol-5-yl]pyridin-3-yl}-1-benzothien-5-yl)-3-[4-chloro-3-(trifluoromethyl)phenyl]urea, or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
containing three or more hetero rings · CPC title
- C07D409/14Primary
containing three or more hetero rings · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10011593B2 cover?
- This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell pro…
- Who is the assignee on this patent?
- Allergan Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D409/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).